News

InSphero AG today announced a breakthrough in 3D cell technology for drug discovery and safety testing with the launch of its 3D InSight™ Human Liver Disease Discovery Platform for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The platform has been precisely engineered to include all the human liver cell types and inducers necessary to replicate progression of NASH in patients, from fatty liver (steatosis) to inflammation (NASH) and scarring (fibrosis) of the liver. This game-changing preclinical discovery platform enables scalable in vitro drug efficacy assessment, screening, combinatorial testing as well as the study of complex NASH pathophysiology.

Findings represent key milestone in PATROLS initiative to establish tools for evaluating health and environmental risks of nanomaterials

With 30 years of cumulative experience at Novartis and Janssen, Prof. Wolf strengthens InSphero leadership team and augments 3D model and organ-on-a-chip R&D

Early proof-of-concept studies demonstrate versatility of scalable microfluidic platform for 3D microtissue-based multi-organ models.

Exclusive one-day scientific meeting to discuss practical applications of innovative 3D-cell and organ-on-a-chip technologies to be held April 25, 2019, in Cambridge, MA

Path BioAnalytics will employ InSphero 3D cell technology to produce organoids from primary cystic fibrosis patient tissues to aid in development of new treatments.

AstraZeneca Relies on 3D InSight™ Human Islet Microtissues in Pancreatic Beta-cell Study InSphero human islet model helps reveal the effects of gene silencing on pancreatic

Government research project to predict hepatic clearance of drugs in humans using Akura™ Flow system results in development partnerships with top pharma companies.

Comprehensive, customizable platforms for preclinical drug safety and efficacy testing, coupled with emerging organ-on-a-chip technology, garner investor support

InSphero extends 3D InSight™ Diabetes Discovery Platform to include ALPCO STELLUX® Chemiluminescent ELISA technology for assessment of pancreatic β-cell function.

Global leader in 3D cell culture technology to deliver standardized 3D models in advanced microfluidic format ideal for organ on a chip applications.

Nanosafety experts from more than 30 institutions convene in Swansea, Wales, for PATROLS project kick off meeting.

InSphero demonstrates commitment to customer satisfaction, superior quality, and continuous improvement by adhering to new ISO 9001:2015 standards.

Charles River to license PDX lines to InSphero for development of 3D InSight™ PDX Microtissues, expansion of in vitro oncology services.

InSphero to Present Novel 3D Human Liver Fibrosis Model at Annual Liver Meeting® in Washington, DC. The new 3D InSight™ Human Liver Fibrosis Model represents